CN116782949A - 短链脂肪酸在癌症预防中的用途 - Google Patents

短链脂肪酸在癌症预防中的用途 Download PDF

Info

Publication number
CN116782949A
CN116782949A CN202180090042.7A CN202180090042A CN116782949A CN 116782949 A CN116782949 A CN 116782949A CN 202180090042 A CN202180090042 A CN 202180090042A CN 116782949 A CN116782949 A CN 116782949A
Authority
CN
China
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
compound
administered
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180090042.7A
Other languages
English (en)
Chinese (zh)
Inventor
马克·A·法伊特尔松
阿拉·阿尔祖马尼扬
埃拉·斯佩克特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sfa Treatment Co
Temple Univ School of Medicine
Original Assignee
Sfa Treatment Co
Temple Univ School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sfa Treatment Co, Temple Univ School of Medicine filed Critical Sfa Treatment Co
Publication of CN116782949A publication Critical patent/CN116782949A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180090042.7A 2020-11-12 2021-11-12 短链脂肪酸在癌症预防中的用途 Pending CN116782949A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063112783P 2020-11-12 2020-11-12
US63/112,783 2020-11-12
PCT/US2021/059211 WO2022104116A1 (en) 2020-11-12 2021-11-12 Use of short chain fatty acids in cancer prevention

Publications (1)

Publication Number Publication Date
CN116782949A true CN116782949A (zh) 2023-09-19

Family

ID=81601740

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180090042.7A Pending CN116782949A (zh) 2020-11-12 2021-11-12 短链脂肪酸在癌症预防中的用途

Country Status (8)

Country Link
US (1) US20240009155A1 (enExample)
EP (1) EP4243803A4 (enExample)
JP (1) JP2023549522A (enExample)
KR (1) KR20230127990A (enExample)
CN (1) CN116782949A (enExample)
AU (1) AU2021380836A1 (enExample)
CA (1) CA3198162A1 (enExample)
WO (1) WO2022104116A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025137671A1 (en) 2023-12-22 2025-06-26 Temple University-Of The Commonwealth System Of Higher Education Short chain fatty acid compounds and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107405321A (zh) * 2015-01-23 2017-11-28 坦普尔大学 短链脂肪酸在癌症预防中的应用
US20190307771A1 (en) * 2016-11-11 2019-10-10 The Regents Of The University Of California Methods and compositions for the treatment of cancer and metabolic diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030020482A (ko) * 2001-08-29 2003-03-10 대한민국(서울대학교) 소디움부티레이트를 유효성분으로 하는 항암제
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
WO2018140687A1 (en) * 2017-01-27 2018-08-02 Temple University-Of The Commonwealth System Of Higher Education Use of short chain fatty acids for the treatment and prevention of diseases and disorders
AU2019358875B2 (en) * 2018-10-09 2025-08-21 Monash University Combination therapy for treatment and prevention of autoimmune and inflammatory diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107405321A (zh) * 2015-01-23 2017-11-28 坦普尔大学 短链脂肪酸在癌症预防中的应用
US20180008565A1 (en) * 2015-01-23 2018-01-11 Helena M.G.P.V. Reis Use of Short Chain Fatty Acids in Cancer Prevention
US20190307771A1 (en) * 2016-11-11 2019-10-10 The Regents Of The University Of California Methods and compositions for the treatment of cancer and metabolic diseases

Also Published As

Publication number Publication date
WO2022104116A1 (en) 2022-05-19
EP4243803A1 (en) 2023-09-20
AU2021380836A1 (en) 2023-06-22
EP4243803A4 (en) 2024-10-23
KR20230127990A (ko) 2023-09-01
JP2023549522A (ja) 2023-11-27
US20240009155A1 (en) 2024-01-11
CA3198162A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
Tang et al. Vitamin E reverses multidrug resistance in vitro and in vivo
Ouellet et al. Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation‐positive tumors
Tao et al. Epidermal growth factor receptor inhibitor-induced diarrhea: clinical incidence, toxicological mechanism, and management
PT1663194E (pt) Utilizaã†o de saha para o tratamento de mesotelioma
RU2753523C2 (ru) УЛУЧШЕННЫЙ ТЕРАПЕВТИЧЕСКИЙ ИНДЕКС ИНГИБИТОРОВ ПРОТИВ ИММУННОЙ КОНТРОЛЬНОЙ ТОЧКИ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ, ВКЛЮЧАЮЩЕЙ ЭКСТРАКТ PHY906, ЭКСТРАКТ Scutellaria baicalensis Georgi (S) ИЛИ СОЕДИНЕНИЕ ИЗ ТАКИХ ЭКСТРАКТОВ
EP4406538A1 (en) Treatment of cancer patients having kras mutations
CA2909349A1 (en) Use of a multi-agent composition for treatment of cancer
US20240382512A1 (en) Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
US10022421B2 (en) Treatment of primary and metastatic carcinoma
JP2025114717A (ja) 抗腫瘍剤及び配合剤
Zhou et al. NF‐κB Inhibitor Myrislignan Induces Ferroptosis of Glioblastoma Cells via Regulating Epithelial‐Mesenchymal Transformation in a Slug‐Dependent Manner
Haefner et al. Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors
US10172857B2 (en) Boosting the effect of methotrexate through the combined use with lipophilic statins
Chen et al. Collagen peptides administration in early enteral nutrition intervention attenuates burn-induced intestinal barrier disruption: Effects on tight junction structure
Szałek et al. The pharmacokinetics of the effervescent vs. conventional tramadol/paracetamol fixed-dose combination tablet in patients after total gastric resection
JP2026001113A (ja) 抗腫瘍剤及び配合剤
JP2023549522A (ja) がん予防における短鎖脂肪酸の使用
US12564600B2 (en) System for enhancing therapeutic compliance of the anti-cancer compound E7766
US20200397738A1 (en) Methods for treating cancer and protecting renewable tissues
US11925634B2 (en) Use of koumine in preparation of medicament for treatment of inflammatory bowel disease
EP4104823A1 (en) Inhibitor of aspartic acid synthesis in tumor cells, inhibitor of spheroid formation of tumor cells, inhibitor of tumor cell metastasis, activity enhancer of glycolytic inhibitor, and pharmaceutical composition for suppressing and/or preventing tumor metastasis
Biswasroy et al. In Silico based-molecular Screening and Evaluation of In-vivo Anti-inflammatory activity of selected medicinal herbs for Psoriasis management
RU2849641C1 (ru) Терапевтическое средство против жировой болезни печени
Jin et al. Peoniflorin Alleviates Corticotropin-Releasing Factor-Induced Irritable Bowel Syndrome by Improving the Intestinal Barrier Function through the Inhibition of the CRFR1/ROCK2/MLC Signaling Pathway
Yang et al. IDDF2019-ABS-0325 Superior efficacy and long-term survival benefit of HDAC8 and PD-L1 co-blockade in liver cancer immunotherapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination